INTERESTING COMPANIES FOUND

PolyCore Therapeutics (2014, Philadelphia) – Developing Dopamine agonists for the treatment of Parkinson’s disease. It is an alternative to current standard-of-care, L-dopa, in the treatment to Parkinson’s, which has problems with side effects and resistance.

HIGHLIGHTS OF THE DAY

  • Bavarian Nordic & BMS initiate Phase II study for 2nd checkpoint/cancer vax combo of their $1B pact. Read More
  • AbbVie grapples with another setback as 2 PhIII trials for its PARP veliparib flop. Read More
  • Ultrgenyx reports positive Phase III data for Kyowa Hakko Kirin-partnered, X-linked hypophosphatemia drug. Read More
  • EU crushes UK hopes of retaining EMA after Brexit. Read More
  • Lion Biotechnologies teams up with MD Anderson Cancer Center on TIL tech. Read More

Leave a Reply